Ingalls & Snyder LLC Cel Sci Corp Transaction History

Ingalls & Snyder LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$2.17 - $3.13 $3,472 - $5,008	-1,600 Reduced 13.66%	10,110 $23,000
Q4 2022 Jan 31, 2023	SELL	$1.99 - $3.52 $76,226 - $134,833	-38,305 Reduced 76.59%	11,710 $28,000
Q3 2022 Oct 21, 2022	SELL	$3.09 - $5.23 $15,450 - $26,150	-5,000 Reduced 9.09%	50,015 $155,000
Q1 2022 May 09, 2022	BUY	$3.93 - $7.7 $7,172 - $14,052	1,825 Added 3.43%	55,015 $216,000
Q4 2021 Feb 11, 2022	SELL	$7.1 - $12.82 $74,692 - $134,866	-10,520 Reduced 16.51%	53,190 $378,000
Q3 2021 Oct 27, 2021	BUY	$7.64 - $12.49 $191,458 - $312,999	25,060 Added 64.84%	63,710 $700,000
Q1 2021 Apr 21, 2021	BUY	$12.0 - $27.64 $240,000 - $552,800	20,000 Added 107.24%	38,650 $588,000
Q4 2020 Jan 27, 2021	BUY	$11.05 - $16.62 $206,082 - $309,963	18,650 New	18,650 $217,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

Stay updated on Ingalls & Snyder LLC with notifications on news.